Patient-Activated Implantable Drug Delivery System for Treatment of Vasovagal Syncope: A Simple Solution?

  • A. Raviele
  • F. Giada
  • G. Gasparini
  • S. Themistoclakis
  • A. Bonso
  • A. Corrado
Conference paper


Vasovagal events, like many other autonomic nervous system disturbances, have a cyclic and unpredictable course with usually brief periods of symptom recrudescence (so-called “clusters”) alternating with sometimes very long periods of quiescience and asymptomatic status [1, 2]. Thus, chronic therapy with drugs does not appear indicated in the majority of cases and is often associated with serious or intolerable side effects as well as poor patient compliance, especially in young people [3]. Moreover, when events occur, prevention of vasovagal reaction usually requires high drug plasma levels which are difficult to attain through chronic oral administration [4]. Indeed, only occasionally have oral drugs proved to be effective in the few double-blind, randomized, placebo-controlled trials performed to date [5–9]. It is also noteworthy that electrical treatment with a pacemaker, even when useful, rarely leads to complete elimination of symptoms [10, 11], because of the hypotensive effects of the vasodepressor reflex that is practically present in all subjects, generally precedes cardioinhibition and bradycardia [12] and is not amenable to correction or reversal by cardiac pacing. For all these reasons, it seems logical and desirable to develop an implantable drug delivery system for treatment of vasovagal syncope [3]. Such a device would allow the automatic “on demand” delivery of a bolus of a vasoactive or a cardioactive drug, previously recognized to be effective and safe in preventing tilt-induced syncope, possibly together with the activation of sequential cardiac pacing.


Drug Delivery System Cardiac Pace Vasovagal Syncope Placebo Injection Vasovagal Reaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sheldon R, Rose S, Flanagan P et al (1996) Risk factors for syncope recurrence after a positive tilt table test in patients with syncope. Circulation 93:973–981PubMedCrossRefGoogle Scholar
  2. 2.
    Raviele A, Themistoclakis S, Gasparini G (1996) Drug treatment of vasovagal syncope. In: Blanc JJ, Benditt D, Sutton R (eds) Neurally mediated syncope: pathophysiology, investigations and treatment. Futura, Armonk, NY, pp 113–117Google Scholar
  3. 3.
    Raviele A, Brignole M, Menozzi C, Giada F (1997) Development of an implantable drug delivery system for the treatment of vasovagal syncope: a dream or a real prospect? In: Raviele A (ed) Cardiac Arrhythmias 1997. Springer-Verlag Italia, Milan, pp 422–427Google Scholar
  4. 4.
    Kelly PA, Mann DE, Adler SW et al (1994) Low dose disopyramide often fails to prevent neurogenic syncope during head-up tilt testing. PACE 11:1202–1206Google Scholar
  5. 5.
    Fitzpatrick AP, Ahmed R, William S, Sutton R (1991) A randomized trial of medical therapy in “malignant vasovagal syndrome” or neurally-mediated bradycardia/hypotension syndrome. Eur J Cardiac Pacing Electrophysiol 2:99–102Google Scholar
  6. 6.
    Brignole M, Menozzi C, Gianfranchi L et al (1992) A controlled trial of acute and long-term medical therapy in tilt-induced neurally mediated syncope. Am J Cardiol 70:339–342PubMedCrossRefGoogle Scholar
  7. 7.
    Morillo CA, Leitch JW, Yee R, Klein GJ (1993) A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt. J Am Coll Cardiol 22:1843–1848PubMedCrossRefGoogle Scholar
  8. 8.
    Raviele A, Brignole M, Sutton R et al (1999) Effect of etilefrine in preventing syncopal recurrence in patients with vasovagal syncope. A double-blind, randomized, placebocontrolled trial. Circulation 99:1452–1457PubMedCrossRefGoogle Scholar
  9. 9.
    Di Girolamo E, Di Iorio C, Sabatini P et al (1999) Effects of paroxetine hydro chloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 33:1227–1230PubMedCrossRefGoogle Scholar
  10. 10.
    Petersen MEV, Chamberlain-Webber R, Fitzpatrick AP, Ingram A, Williams T, Sutton R (1994) Permanent pacing for cardioinhibitory malignant vasovagal syndrome. Br Heart J 71:274–281PubMedCrossRefGoogle Scholar
  11. 11.
    Connolly SJ, Sheldon R, Roberts RS, Gent M (1999) The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol 33:16–20PubMedCrossRefGoogle Scholar
  12. 12.
    Raviele A, Gasparini G, Di Pede F, Delise P, Bonso A, Piccolo E (1990) Usefulness of head-up tilt test in evaluating patients with syncope of unknown origin and negative electrophysiologic study. Am J Cardiol 65:1322–1327PubMedCrossRefGoogle Scholar
  13. 13.
    Brignole M, Menozzi C, Corbucci G, Garberoglio B, Plicchi G (1997) Detecting incipient vasovagal reaction: intraventricular acceleration. PACE 20(Pt.II):801–805PubMedCrossRefGoogle Scholar
  14. 14.
    Nappolz T (1994) Combination of drug delivery systems and implantable cardioverter-defìbrillators: is there a possible marriage? In: Singor I (ed) Implantable cardioverter-defìbrillator. Futura, Armonk, NY, pp 731–749Google Scholar
  15. 15.
    La Rovere MT, Specchia G, Mortara A, Schwartz PJ (1988) Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction. A prospective study. Circulation 78:816–824PubMedCrossRefGoogle Scholar
  16. 16.
    Arky R (1996) Physicians’ Desk Reference. Medical Economic Company, Montvale, NYGoogle Scholar
  17. 17.
    Hengstmann JH, Goronzy J (1982) Pharmacokinetics of 3H phenylephrine in man. Eur J Clin Pharmacol 21:335–341PubMedCrossRefGoogle Scholar
  18. 18.
    USPDI (1996) Drug information for the health care professional, 16th ed. US Pharmaceutical Convention, Rockville, MdGoogle Scholar
  19. 19.
    Reynolds JEF (1993) Martindale: The Extra Pharmacopoeia. The Pharmaceutical Press, LondonGoogle Scholar
  20. 20.
    Weber JC, Gupta VD (1970) Stability of phenylephrine HCl in intravenous solutions. Am J Hosp Pharm 28:200Google Scholar
  21. 21.
    Giada F, Raviele A, Giardiello G, De Seta F (1999) Evaluation of efficacy of phenylephrine to abort syncope during tilt table testing: the first step for the development of an implantable drug delivery system for treatment of vasovagal syncope. PACE 22:756 (abstr)Google Scholar
  22. 22.
    Raviele A, Menozzi C, Brignole M et al (1995) Value of head-up tilt testing potentiated with sublingual nitroglycerin to assess the origin of unexplained syncope. Am J Cardiol 76:267–272PubMedCrossRefGoogle Scholar
  23. 23.
    Giada F, Themistoclakis S, Brignole M et al (1997) Short-duration pharmacological head-up tilt test: low-dose isoproterenol or nitroglycerin? J Am Coll Cardiol 29:468A (abstr)Google Scholar
  24. 24.
    Strieper MJ, Campbell RM (1993) Efficacy of alpha-adrenergic agonist therapy for prevention of pediatric neurocardiogenic syncope. J Am Coll Cardiol 22:594–597PubMedCrossRefGoogle Scholar
  25. 25.
    Mangru NN, Young ML, Mas MD, Chandar JS, Pearse LA, Wolff GS (1996) Usefulness of tilt test with normal saline solution infusion in management of neurocardiac syncope in children. Am Heart J 131:953–955PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2000

Authors and Affiliations

  • A. Raviele
    • 1
  • F. Giada
    • 1
  • G. Gasparini
    • 1
  • S. Themistoclakis
    • 1
  • A. Bonso
    • 1
  • A. Corrado
    • 1
  1. 1.Divisione di CardiologiaOspedale Umberto IMestre, VeniceItaly

Personalised recommendations